Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to find a better, more convenient way to improve anemia results by increasing the amount of medication given at 3 week intervals. Researchers want to know if giving a higher dose of Procrit® and intravenous (IV) iron once every 3 weeks would give better results in treating anemia without the need for more office visits.
| Condition | Intervention | Phase |
|---|---|---|
|
Anemia |
Drug: Epoetin Alfa plus Iron |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II Trial Using Intravenous Iron in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia Treated With 120,000 Units Epoetin Alfa Every Three Weeks |
- Achieve hemoglobin responses > 2g/dl in at least 70% of patients [ Time Frame: Nine weeks, after at least two doses of 120,000 units epoetin alfa ] [ Designated as safety issue: No ]
- Descriptive evaluation of adverse effects of parenteral iron and epoetin alfa 120,000 units given every three weeks [ Time Frame: Patient follow up until week 12 ] [ Designated as safety issue: Yes ]
| Enrollment: | 0 |
| Study Start Date: | May 2007 |
| Study Completion Date: | November 2009 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Epoetin Alfa plus Iron |
Drug: Epoetin Alfa plus Iron
These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount. In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan. Other Name: Procrit®; Ferrlecit®
|
Detailed Description:
There are more than 170,000 patients diagnosed with lung cancer in the United States each year and many will develop anemia (iron deficiency) during the course of treatment. Anemia is associated with poor quality of life and treatment delays for advanced lung cancer. The treatment of iron deficiency anemia is with iron. Iron is an essential mineral used in red blood cells to carry oxygen throughout the body. Iron is necessary to make hemoglobin, a key element in red blood cells.
The FDA has approved Procrit® (epoetin alfa) to treat anemia in people with non-myeloid (bone marrow) malignancies. Procrit® is a man-made, injectable drug for treating anemia and it encourages red cell production. While the administration of intravenous iron therapy, injected into veins through an IV, did increase the response rate of Procrit® in a previous study, researchers want to find out the best amount of drug to use and the best time to administer Procrit®, along with ferric gluconate, (Ferrlecit®), added for lack of iron.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed small cell or non small cell lung cancer
- Stage III or Stage IV lung cancer
- Platinum containing chemotherapy induced anemia (< 10 g/dl Hb)
- Cancer related anemia (<10 g/dl Hb) at time of initiation of chemotherapy
- ECOG performance status of 0,1, or 2
- Informed consent
- Age>18
- Expected to receive platinum based outpatient chemotherapy for at least nine weeks
Exclusion Criteria:
- Pregnant women
- Intolerance to epoetin alfa or parenteral iron
- More than 2 cycles of the planned platinum chemotherapy at time of enrollment
- Chronic GI bleed (> than 4 weeks positive hemoccult or gastroccult)
- Ferritin > 500 mg/dl
- Anemia due to other causes than cancer or chemotherapy
- Previous parenteral iron therapy
- Uncontrolled hypertension (systolic BP > 160, diastolic > 100 mmHg)
Contacts and Locations| United States, Kentucky | |
| James Graham Brown Cancer Center | |
| Louisville, Kentucky, United States, 40202 | |
| Principal Investigator: | Goetz H Kloecker, MD | James Graham Brown Cancer Center, Univeristy of Louisville |
More Information
Additional Information:
No publications provided
| Responsible Party: | James Graham Brown Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00481624 History of Changes |
| Other Study ID Numbers: | 07.0210 |
| Study First Received: | June 1, 2007 |
| Last Updated: | May 14, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by James Graham Brown Cancer Center:
|
advanced lung cancer Procrit Epoetin Alfa Ferric Gluconate iron supplementation |
Additional relevant MeSH terms:
|
Anemia Lung Neoplasms Hematologic Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Ferric gluconate |
Epoetin Alfa Iron Hematinics Hematologic Agents Therapeutic Uses Pharmacologic Actions Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013